AnaptysBio, Inc
Price
FilingsNewest: 8-K, Financial statements and exhibitsSep 21 →InsidersNo open-market buys. 7 insiders sold $9.5M, 10 of 41 sales on a 10b5-1 plan.→HoldersEcoR1 Capital 26.5%BlackRock 6.2%Tang 4.5%→Financing →PeersClosest companies: SEER, BLFS, NET→
From the filings
Figures
- Revenue
- $232.4Mlast 12 months
- Net income
- −$26.8Mlast 12 months
- Operating cash flow
- $4.5Mlast 12 months
- Cash and equivalents
- $133.8Mat the last balance sheet
- Shares outstanding
- 29.7M shareson issue